Key Metrics
CiteScore 

19.9
SNIP 

5
Recommended pre-submission checks
Powered by 

Topics Covered on The Lancet Haematology
The Lancet Haematology Journal Specifications
Indexed in the following public directories
Web of Science
Scopus
SJR
| Overview | |
| Publisher | ELSEVIER SCI LTD |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 2014 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in The Lancet Haematology ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in The Lancet Haematology
Patient selection and treatment sequencing in RESMAIN.
- 1 Apr 2026
- The Lancet. Haematology
Balancing the benefits and risks of rebalancing coagulation in haemophilia.
- 1 Apr 2026
- The Lancet. Haematology
Oral deucrictibant for prophylaxis of hereditary angioedema attacks (CHAPTER-1): primary analysis of a randomised, double-blind, placebo-controlled, phase 2 trial.
- 1 Apr 2026
- The Lancet. Haematology
From diagnosis to equitable care in bleeding disorders.
- 1 Apr 2026
- The Lancet. Haematology
Who will watch the watchmen: unique challenges of T-cell redirecting therapies in T-cell malignancies.
- 1 Apr 2026
- The Lancet. Haematology
Patient selection and treatment sequencing in RESMAIN - Author's reply.
- 1 Apr 2026
- The Lancet. Haematology
Patient selection and treatment sequencing in RESMAIN.
- 1 Apr 2026
- The Lancet. Haematology
Balancing the benefits and risks of rebalancing coagulation in haemophilia.
- 1 Apr 2026
- The Lancet. Haematology
Oral deucrictibant for prophylaxis of hereditary angioedema attacks (CHAPTER-1): primary analysis of a randomised, double-blind, placebo-controlled, phase 2 trial.
- 1 Apr 2026
- The Lancet. Haematology
From diagnosis to equitable care in bleeding disorders.
- 1 Apr 2026
- The Lancet. Haematology
Who will watch the watchmen: unique challenges of T-cell redirecting therapies in T-cell malignancies.
- 1 Apr 2026
- The Lancet. Haematology
Patient selection and treatment sequencing in RESMAIN - Author's reply.
- 1 Apr 2026
- The Lancet. Haematology